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Abstract
Background: Cytomegalovirus seropositivity is an independent risk factor for atherosclerosis in patients with ESRD.
Donor CMV seropositivity is associated with higher graft loss. Dendritic cells, macrophages and Th17 lymphocytes
are defined as producers of IL-23. IL-23 is thought to be involved in the promotion of Th17 cell polarization. Latent
CMV-induced Th17 might be involved in the pathogenesis of CMV infection in patients with ESRD. We aimed to
evaluate associations of Th17-dependent cytokines with ESRD, CMV status and post-transplant outcome in kidney
transplantation.
Results: IL-21 plasma levels were similar in patients and healthy controls (p = 0.47), whereas IL-9 (p = 0.02) and IL-23
(p < 0.0001) levels were significantly higher in ESRD patients. CMV-seronegative (p = 0.002) and –seropositive
(p < 0.001) patients had significantly higher IL-23 plasma levels than controls. CMV-seropositive patients showed
excessively higher IL-23 (p < 0.001) plasma levels than CMV-seronegative patients. Patients with post-transplant CMV
reactivation had higher IL-23 plasma levels than patients without CMV reactivation (p = 0.025).
Conclusions: Our results indicate that latent CMV induces IL-23. IL-23 might be an inflammatory mediator of latent
CMV infection in patients with ESRD and predisposes patients for post-transplant CMV reactivation.
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Background
End-stage renal diseases (ESRD) are associated with
immunodeficiency and inflammation [1]. Previous stud-
ies reported on reduced numbers of circulating naive T
cells, suggesting to indicate a reduction of Treg subpop-
ulations as well [1]. Post-transplant immunologic
responses are regulated by T helper (Th)1 or Th2 cells
[2, 3]. The Th17 cells are a subset of effector- Th which
specifically secretes IL-17. The cytokine IL-23 is
produced by dendritic cells, macrophages, and Th17
pro-inflammatory cells [4, 5]. IL-23 is thought to be
involved in the promotion of Th17 cell polarization.
Th17 cells produce IL-17 and IL-22 and play an essential
role in inflammatory diseases [5, 6]. Th2 cells were
initially described as the main source of IL-9 [7]. Aside
from them Th9, Th17 and peripherally induced T regu-
latory (iTreg) cells were also capable of producing IL-9
[7]. IL-9 is a plethoric cytokine and plays a role in
allergy, inflammation, and cancer [7].
CMV infection is an unexpectedly high and independ-
ent risk factor for atherosclerosis in patients with ESRD,
HIV+ patients and healthy individuals [8–12]. A recent
study demonstrated a reduced rate of cardiovascular
death after cytomegalovirus prophylaxis in renal
transplant patients [13]. During the progression of renal
failure in patients with chronic kidney disease, numbers
of CMV-specific T cells increased [8]. Without CMV
prophylaxis, donor and recipient CMV seropositivity are
detrimental factors for long-term renal allograft survival
and post-transplant CMV infection [14–16] whereas
CMV prophylaxis prevented acute rejection (AR) and
improved graft function [17]. It has been suggested that
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Th17 activation might contribute to the pathogenesis of
latent CMV infection [18]. The association of Th17,
IL-17 and Th17-dependent cytokines such as IL-21 with
ESRD and transplantation outcome has been studied
previously [18–26]. We aimed to evaluate the association
of Th17-dependent cytokines in potential kidney trans-
plant recipients with ESRD and CMV seropositivity and
we tried to calculate the predictive value of these
cytokines for post-transplant outcome.
Methods
Demographic data
The study was approved by the Ethical Committee of
the University of Heidelberg. Pre-operative plasma levels
of the cytokines IL-9, IL-21 and IL-23 were measured in
117 patients with ESRD (aged 49.8 ± 16.3 years, 54
female) who underwent kidney transplantation. Seventy
patients from our center were followed for 1 year at the
Heidelberg transplantation center and post-transplant
events such as AR, DGF, graft loss and viral infections
including CMV and BK-virus were analyzed. Recipient
characteristics are shown in Table 1. ESRD was caused
by glomerulonephritis, pyelonephritis, polycystic disease,
diabetes or autoimmune diseases. Only one patient
received preemptive kidney transplant. Mean duration of
pre-transplant dialysis was 65.5 ± 51.5 months (rage:
2–304). There were 16 retransplant patients with non-
significant different distribution in the 2 patient groups.
The post-transplant administered immunosuppressive
regimens were similar in the two groups (Table 1).
Patients were classified as either CMV+ (n = 68) or
CMV- (n = 49) by CMV serostatus. Post-transplant CMV
pp65 antigenemia was determined and the presence of
>3 detectable CMV pp65 positive cells in 500,000
peripheral leukocytes was defined as reactivation or
symptomatic infection [27]. The CMV reactivation was
confirmed by CMV-DNA detection in CMV pp65
antigen-positive patients. Routinely, all patients were
monitored for CMV infection starting on day 10 post-
transplant. Recipients who received kidneys from CMV-
negative donors were evaluated for CMV pp65 antigen
during the first 6 months post-transplant monthly and
yearly thereafter. All recipients who obtained D+ kidneys
received CMV prophylaxis with 900 mg daily valganci-
clovir for 3 months and were tested weekly during the
first 3 months post-transplant, twice monthly for 4 to
6 months post-transplant, monthly for 7 to 12 months
post-transplant, and 1 to 4 times yearly thereafter. The
administration of CMV prophylaxis explains the
relatively low percentage of patients with active CMV
infection eligible for our study. Post-transplant BKV was
determined by quantitative analysis of BKV DNA. More
than 100 BKV copies/mL denotes as (re) activated infec-
tion. Twenty-seven healthy controls with no known ac-
tive infectious and other inflammatory diseases served as
controls to establish references for the studied cytokines.
Determination of CMV activation
DNA detection and PCR amplification
CMV DNA was extracted as previously reported [28].
Briefly CMV DNA was extracted from 200 μl EDTA
blood samples and purified using the QIAamp blood kit
(QIAGEN, Hilden, Germany). For amplification of CMV
IE-1 gene DNA, a nested PCR consisting of two succes-
sive sets of 35 cycles was performed in a Gene Amp
PCR System 2400 thermocycler (Perkin Elmer, Norwalk,
CT). All DNA extraction and amplification reactions
carried appropriate parallel negative controls to detect
contamination at any stage in the procedure. PCR
products were electrophoresed in a 2 % agarose gel
containing 0.5 mg/ml ethidium bromide and visualized
under ultraviolet illumination.
CMV pp65 antigen detection
CMV pp65 antigen was detected as previously reported
[29]. Briefly, about 8 mL of EDTA blood was used for
isolation of leukocytes and 500,000 leukocytes were spun
carefully on a slide using a cytospin centrifuge. Cells
were fixed and stained with an anti-CMV pp65 mouse
monoclonal antibody, washed, and further incubated
with an anti-mouse-immunoglobulin G FITC-labeled
antibody. More than 3 positive leukocytes per 500,000
cells denote an activated CMV infection [27].
Table 1 IL-9, IL-21 and IL-23 plasma levels in healthy controls
and ESRD patients with and without CMV seropositivity
Parameters Controls (n = 27) ESRD (n = 117) p
IL-9 (pg/ml) 799 ± 2203 435 ± 930 0.74
IL-21 (pg/ml) 368 ± 751 194 ± 213 0.61
IL-23 (pg/ml) 2.9 ± 11 10 ± 17 <0.001
Controls (n = 27) CMV-IgG- (n = 49)
IL-9 (pg/ml) 799 ± 2203 336 ± 810 0.53
IL-21 (pg/ml) 368 ± 751 156 ± 175 0.25
IL-23 (pg/ml) 2.9 ± 11 5.4 ± 7.8 0.002
Controls (n = 27) CMV-IgG+ (n = 68)
IL-9 (pg/ml) 799 ± 2203 506 ± 1007 0.31
IL-21 (pg/ml) 368 ± 751 221 ± 235 0.96
IL-23 (pg/ml) 2.9 ± 11 14 ± 20 <0.0001
CMV-IgG- (n = 49) CMV-IgG+ (n = 68)
IL-9 (pg/ml) 336 ± 810 506 ± 1007 0.02
IL-21 (pg/ml) 156 ± 175 221 ± 235 0.12
IL-23 (pg/ml) 5.4 ± 7.8 14 ± 20 <0.001
Mann-Whitney-U test was used to calculate p values
Data are given as mean ± SD
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Detection of active BKV infection by real-time PCR
BKV infection was detected as previously reported
[30]. Briefly, Nucleic acid was isolated from untreated
plasma using the QIAamp blood kit (Qiagen; Hilden;
Germany) according to the manufacturer’s instruc-
tions. For quantitative analysis of BKV DNA, 5 μL of
extracted nucleic acids was amplified as described
previously [30]. More than 100 BKV copies/mL denote
an activated infection [31].
Sample collection and determination of plasma IL-9, IL-21
and IL-23
All samples were collected immediately before trans-
plantation. Within 2 h after the blood was drawn
plasma was separated from cells by centrifugation at
1550 × g for 10 min. The plasma was snap frozen and
stored at -30 °C until testing. The plasma levels of IL-9,
IL-21 and IL-23 were measured with a commercial test
developed by Komabiotech South Korea using ELISA
kits. Captured antibodies were added to previously
coated plates with cytokine antibodies and incubated.
Biotinylated detection antibody was added to each test
well and incubated. HRP-conjugated streptavidin was
added to each well. Then color development enzyme
was added to each well and after 15 min the results
were obtained by measuring the absorbance reading.
The protocol provided by the assay manufacturer was
strictly followed and all samples were tested undiluted
according to the instructions of the manufacturer. Each
sample was tested in duplicate and the mean of each
sample was analyzed.
Statistical analyses
Categorical and continuous variables were analyzed
using chi square, Fisher exact and Mann-Whitney-U
tests. The most sensitive cut-off values were calculated
by ROC curve analysis. Uni- and multivariable logistic
regression analyses were applied to identify risk factors
for CMV (re) activation. All statistical analyses were
performed with the Statistical Package for the Social
Sciences (SPSS, 18.0; SPSS Inc., Chicago, IL, USA). After
Bonferroni correction, p values <0.05 were defined as
statistically significant.
Results
IL-9, IL-21 and IL-23 levels in healthy controls and patients
with ESRD
Plasma levels of IL-9 (p = 0.74) and IL-21 (p = 0.61) were
similar in patients with ESRD and healthy controls,
whereas the plasma level of IL-23 (p < 0.001) was strongly
increased in patients with ESRD (Fig. 1 and Table 1).
IL-9, IL-21 and IL-23 levels in first transplant and retrans-
plant recipients, in patients with hemodialysis and peri-
toneal dialysis and in male and female patients with ESRD
Plasma levels of IL-9, IL-21 and IL-23 were similar in
first and retransplant recipients (n = 101 and n = 16,
respectively), hemodialysis (n = 99) and peritoneal
dialysis (n = 17) as well as in male and female patients
(p = n.s.; data not shown). Although CMV-seropositive
patients had significantly longer pre-transplant dialysis
time, there were no correlations between pre-transplant
dialysis time (IL-9: p = 0.78, IL-21: p = 0.97 and IL-23:
p = 0.96, respectively), serum Cr (p = 0.68, p = 0.36 and
p = 0.73, respectively), recipient’s age (p = 0.28, p = 0.11
and p = 0.33, respectively) and IL-9, IL-21 and IL-23
levels.
IL-9, IL-21 and IL-23 levels in patients with and without
CMV seropositivity
Interestingly, CMV-seronegative (p = 0.002) as well as
CMV-seropositive (p < 0.001) patients showed higher
IL-23 plasma levels than healthy controls (Fig. 2 and
Table 1). Furthermore, CMV-seropositive patients
showed significantly higher IL-23 plasma levels than
CMV-seronegative recipients (p < 0.001) (Table 1). IL-9
and IL-21 plasma levels in ESRD, CMV-seronegative and
CMV-seropositive patients were similar to those in
healthy individuals (p = n.s.). There was a trend of higher
IL-9 plasma levels in CMV-seropositive compared with
CMV-seronegative patients (p = 0.02) whereas IL-21 was
similar in both patient groups (p = 0.12) (Table 1). IL-17
levels were measured in 53 plasma samples. In 25
plasma samples IL-17 was not detectable. Sixteen of 25
CMV-IgG- and 9 of 28 CMV-IgG+ patients had
undetectable IL-17 (p = 0.02) and CMV-IgG+ patients
showed a trend of higher IL-17 plasma levels than
patients without CMV-IgG (7.5 ± 7.4 pg/ml vs 5.2 ± 10.0:
p = 0.06) suggesting that Th17 cells were activated
(Fig. 3).
IL-9, IL-21 and IL-23 levels in patients with and without
post-transplant events
Seventy patients were followed for 1 year post-
transplant. Eight patients experienced AR (Banff classifi-
cation 2007; Ia, IIb and III), 27 patients borderline
rejection (BR) and 20 patients DGF. Six patients had
biopsy-proven ATN. Plasma levels of IL-9, IL-21 and
IL-23 were similar in patients with and without post--
transplant AR, BR, patients with and without rejection
(AR + BR), ATN or DGF (Table 2). Twenty-four patients
showed evidence of viral infection, thereof BK-virus in-
fection in 11, CMV infection in 7 and CMV plus BK-
virus infection in 6 patients. Only one patient had
biopsy-proven BKV nephropathy. Median value of BKV
was 30×107 copies/ml plasma (range: 17×104−58×109).
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Median duration of BKV viremia was 173 days (range:
19–365 days). CMV-seronegative recipients (R-) who re-
ceived grafts from CMV-seronegative donors (D-) (D-/
R-; n = 14) did not experience CMV infection. In con-
trast, 4 of 21 (19 %) D+/R-, 6 of 14 (43 %) D-/R+ and 3
of 22 (14 %) D+/R+ transplants developed CMV infec-
tion/reactivation including hepatitis, GI-bleeding,
viremia, thrombocytopenia, pneumonia, colitis, esopha-
gitis with antigenemia (n = 13; 239 ± 379 pp65 antigen
+/500,000 leucocytes, range 10–1138) and viremia (n = 8;
449240 ± 521917 CMV-DNA copies/ml). Ten of 13
patients with CMV (re) infection had higher IL-23 than
median and 3 of 13 lower than median value (p = 0.02).
Patients with CMV or CMV plus BKV infection had
Fig. 1 IL-23 plasma levels in patients with ESRD (n = 117) and healthy controls (n = 27). Plasma IL-23 levels were determined retrospectively using
ELISA kits and data were statistically analyzed using Mann-Whitney-U test. Horizontal bars show median values in each study group. ESRD patients
had significantly higher IL-23 levels pre-transplant than healthy controls
Fig. 2 IL-23 plasma levels in ESDR patients with CMV-IgG status and healthy controls. Plasma IL-23 levels were determined retrospectively using
ELISA kits and data were statistically analyzed using Mann-Whitney-U test. Horizontal bars show median values in each study group. CMV-IgG+
ESDR patients (n = 69) had significantly higher IL-23 levels pre-transplant than CMV-IgG- ESDR patients (n = 48) and healthy controls (n = 27)
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similar plasma levels of cytokines as patients with BK
infection only (p = n.s.; data not shown) suggesting that
CMV as well as BKV infections increase IL-9, IL-21, and
IL-23 cytokine levels. However, patients with
post-transplant CMV disease (n = 13; 150 ± 106 days post-
transplant, range 41–363 days) had higher pre-transplant
plasma levels of IL-23 (8.6 ± 4.4 vs 8.0 ± 17: p = 0.025) and
IL-23/Cr ratios (p = 0.040) than patients without CMV
disease after transplantation (n = 57), suggesting an associ-
ation of high IL-23 plasma levels with CMV antigenemia
and symptomatic CMV (re) infection post-transplant
(Fig. 4). Plasma levels of IL-9 (p = 0.80), IL-21 (p = 0.39),
IL-9/Cr (p = 0.67) and IL-21/Cr (p = 0.34) were not statis-
tically different between the two groups. Regression
analysis indicated that a pre-transplant IL-23 plasma level
of >7 pg/ml is a risk factor for post-transplant CMV
Fig. 3 IL-17 plasma levels in ESDR patients with CMV-IgG status. Plasma IL-17 levels were determined retrospectively using ELISA kits and data
were statistically analyzed using Mann-Whitney-U test. Horizontal bars show median values in each study group. CMV-IgG+ ESDR patients (n = 28)
had significantly higher IL-17 levels pre-transplant than CMV-IgG- ESDR patients (n = 25). In 25 plasma samples IL-17 was not detectable. Sixteen
of 25 CMV-IgG- and 9 of 28 CMV-IgG+ patients had undetectable IL-17 (p = 0.02) and CMV-IgG+ patients showed a trend of higher IL-17 plasma
levels than patients without CMV-IgG suggesting that Th17 cells were activated
Table 2 IL-9, IL-21 and IL-23 plasma levels in patients with and
without post-transplant events
Patients IL-9 IL-21 IL-23
p p p
AR+ (n = 8) vs AR- (n = 109) 0.43 0.84 0.54
BR+ (n = 27) vs BR- (n = 90) 0.71 0.93 0.13
AR + BR+ (n = 35) vs AR- (n = 82) 0.44 0.85 0.28
DGF+ (n = 20) vs DGF- (n = 97) 0.95 0.42 0.46
ATN+ (n = 6) vs DGF- (n = 111) 0.60 0.60 0.07
Mann-Whitney-U test was used to calculate p values
Data are given as mean ± SD
Fig. 4 Pre-transplant IL-23 plasma levels in kidney transplant recipients
with and without post-transplant CMV infection. Plasma IL-23 levels
were analyzed retrospectively using ELISA kits and data were
statistically analyzed using Mann-Whitney-U test. Horizontal bars show
median values in each study group. Patients with post-transplant CMV
infection (n = 13) had significantly higher IL-23 levels pre-transplant
than patients without CMV infection (n = 57) and healthy
controls (n = 27)
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infection/reactivation and symptomatic infection (RR =
4.50, confidence interval 1.23–16.52: p = 0.023). ROC
curve analysis with respect to post-transplant CMV dis-
ease showed a sensitivity of 69 % and a specificity of 67 %
at a cut-off value for IL-23 of ≥7 pg/ml (p = 0.025) (Fig. 5).
Discussion
Post-transplant CMV reactivation and active infection
continues to be a major risk factor for transplant recipi-
ents [32]. CMV (re) infection is one of the most frequent
causes of morbidity and mortality in transplant recipients
early and late post-transplant [33, 34]. It was reported that
CMV infection is an independent risk factor for athero-
sclerosis and A-V fistula in hemodialysis patients [8–10,
35, 36]. Thus, there is a need to identify pre-transplant pa-
tients at risk of developing CMV disease post-transplant
in spite of the administration of CMV prophylaxis.
Our data show that pre-transplant IL-23 plasma levels
>7 pg/ml are associated with a high risk of developing
CMV disease during the first year post-transplant. High
IL-23 plasma levels indicate a strong activation of Th17
lymphocytes, dendritic cells and macrophages. Th17
lymphocytes might be involved in the elimination of
virus-infected cells and might represent a sensitive tool
for identifying patients with replicating virus [18, 37]. A
high proportion of IL-17 positive patients and a trend of
higher IL-17 plasma levels in our CMV-IgG positive
patients is in agreement with previous results. Part of
the ESRD patients harbor virus whose replication rate is
low and inhibited by the patient’s immune system (latent
infection). However, when these patients receive
immunosuppression post-transplant, the treatment-
impaired immune system is unable to suppress virus
replication and the patient develops CMV disease,
associated with early death or atherosclerosis as long-
term consequence [38] The use of valaciclovir, valganci-
clovir or ganciclovir for 3 to 6 months is an effective
prophylaxis of cytomegalovirus disease in high risk
patients. However, CMV prophylaxis does not prevent
CMV disease in every recipient of a CMV-seropositive
transplant. Our data show that CMV-seropositive as well
as CMV-seronegative recipients who had received
organs from seropositive donors are at high risk of post-
transplant CMV reactivation despite CMV prophylaxis.
Pre-transplant IL-23 measurement as a surrogate marker
might identify patients with ongoing anti-CMV
responses that might lead to developing CMV disease
post-transplant. Post-transplant IL-23 monitoring as
surrogate marker might indicate strong CMV replication
despite CMV prophylaxis, suggesting the need of
additional treatment options to cure impending CMV
disease. Because Th17 lymphocytes might be involved in
the elimination of virus-infected cells, IL-23 levels might
reflect the potential of the immune system during im-
munosuppressive therapy to eliminate virus-producing
cells. It appears from our data that the Th17 activation
in patients with CMV disease was not strong enough to
inhibit CMV replication. Therefore, it should be consid-
ered whether patients with excessively high IL-23 should
receive more individualized immunosuppressive treat-
ment in order to prevent over-immunosuppression and
active virus disease. Similar to high-risk bone marrow
Fig. 5 ROC curve analysis for the calculation of diagnostic accuracy, cut-off value, sensitivity and specificity of pre-transplant IL-23 plasma levels to
predict post-transplant CMV reactivation in patients. At a cut-off value for IL-23 of ≥7 pg/ml ROC curve analysis showed a sensitivity of 69 % and
a specificity of 67 %, a PPV of 31 % and a NPV of 89 %
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transplant recipients, kidney transplant recipients with
pre-transplant high IL-23 might be candidates of immu-
nomodulatory therapy against CMV infection, including
intravenous immune globulin and cytomegalovirus
hyperimmune globulin as well as adoptive transfer of
CMV-specific T-cells and donor/recipient vaccination
strategies [39]. Further comparative studies of patients
with and without high IL-23 are needed to confirm our
results and our conclusion [40–43].
Conclusion
Our data suggest that CMV-seropositive patients with
high pre-transplant IL-23 should preferentially receive a
CMV-seronegative graft in order to lower the risk of post-
transplant CMV disease. IL-23 monitoring pre- and post-
transplant might enable decisions concerning treatment
options with the aim to decrease the risk of the post-
transplant complications such as CMV disease and one
might speculate that CMV prophylaxis in renal transplant
recipients might reduce the rate of cardiovascular death.
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